SCHEMBL320951

SCHEMBL320951

CCO[Si](CCCCCCCCl)(OCC)OCC

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523662 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4526313 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4530475 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4524574 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4521233 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4523393 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4529248 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4524161 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4539158 1.00 TSHR (0.42) TSHRALDH1A1TDP1
SCHEMBL4517329 1.00 TSHR (0.42) TSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12163050-B2 Invisible-fingerprint coatings and process for forming same HENKEL AG & CO. KGAA (DE) 2024-12-10 US claimed
US-20200277513-A1 INVISIBLE-FINGERPRINT COATINGS AND PROCESS FOR FORMING SAME HENKEL AG & CO. KGAA (DE) 2020-09-03 US claimed
WO-2025034909-A1 NON-FLUORINATED INVISIBLE FINGERPRINT COATINGS HENKEL AG & CO. KGAA (DE) 2025-02-13 WO disclosed
US-12163050-B2 Invisible-fingerprint coatings and process for forming same HENKEL AG & CO. KGAA (DE) 2024-12-10 US disclosed
US-20200277513-A1 INVISIBLE-FINGERPRINT COATINGS AND PROCESS FOR FORMING SAME HENKEL AG & CO. KGAA (DE) 2020-09-03 US disclosed
EP-2990113-B1 METHOD FOR PRODUCING CATALYST FOR CYCLIC CARBONATE SYNTHESIS MARUZEN PETROCHEM CO LTD (JP) 2020-03-25 EP disclosed
EP-2990112-B1 METHOD FOR MANUFACTURING CATALYST FOR SYNTHESIZING CYCLIC CARBONATE MARUZEN PETROCHEM CO LTD (JP) 2020-03-25 EP disclosed
US-10221200-B2 Quaternary amino alcohol functional organosilicon compounds, composition containing the latter and their production and use EVONIK DEGUSSA GMBH (DE) 2019-03-05 US disclosed
US-10029241-B2 Method for producing catalyst for cyclic carbonate synthesis MARUZEN PETROCHEMICAL CO., LTD. (JP) 2018-07-24 US disclosed
US-10011621-B2 Method for producing silica gel-immobolized phosphonium salt catalysts MARUZEN PETROCHEMICAL CO., LTD. (JP) 2018-07-03 US disclosed
US-9834536-B2 Method for producing catalyst for cyclic carbonate synthesis NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2017-12-05 US disclosed
EP-2421874-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF Evonik Degussa GmbH (DE) 2012-02-29 EP disclosed
US-20120037040-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF EVONIK DEGUSSA GMBH (DE) 2012-02-16 US disclosed
WO-2012004044-A1 METHODS FOR PRODUCING A DISPERSION CONTAINING SILICON DIOXIDE PARTICLES AND CATIONIZATION AGENT EVONIK DEGUSSA GMBH (DE) 2012-01-12 WO disclosed
US-20120006228-A1 DISPERSION CONTAINING SILICA PARTICLES SURFACE-MODIFIED WITH QUATERNARY, AMINOFUNCTIONAL ORGANOSILICON COMPOUNDS EVONIK DEGUSSA GMBH (DE) 2012-01-12 US disclosed
WO-2010121878-A1 DISPERSION CONTAINING SILICA PARTICLES SURFACE-MODIFIED WITH QUATERNARY, AMINOFUNCTIONAL ORGANOSILICON COMPOUNDS EVONIK DEGUSSA GMBH (DE) 2010-10-28 WO disclosed
WO-2010121873-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF EVONIK DEGUSSA GMBH (DE) 2010-10-28 WO disclosed
US-20090123516-A1 DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-05-14 US disclosed
WO-2007019478-A2 DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-02-15 WO disclosed
US-4390712-A Aqueous solution of cationic organosilicon compounds and process for the production of the solutions DEGUSSA AG (DE) 1983-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10029241-B2 Method for producing catalyst for cyclic carbonate synthesis CYCS, CA7, CA9 TSHR 4511/4885ALDH1A1 3770/4885TDP1 4293/4885
US-10011621-B2 Method for producing silica gel-immobolized phosphonium salt catalysts SIK2, SIK3, SIK1 TSHR 3660/4885ALDH1A1 4167/4885TDP1 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.